ADC Therapeutics (ADCT) Invested Capital (2019 - 2023)
Historic Invested Capital for ADC Therapeutics (ADCT) over the last 4 years, with Q3 2023 value amounting to $55.3 billion.
- ADC Therapeutics' Invested Capital fell 2019.34% to $55.3 billion in Q3 2023 from the same period last year, while for Sep 2023 it was $55.3 billion, marking a year-over-year decrease of 2019.34%. This contributed to the annual value of $506.3 million for FY2022, which is 32408.12% up from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' Invested Capital is $55.3 billion, which was down 2019.34% from $58.0 billion recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Invested Capital registered a high of $79.9 billion during Q1 2022, and its lowest value of $89797.0 during Q3 2021.
- Over the past 4 years, ADC Therapeutics' median Invested Capital value was $27.9 billion (recorded in 2022), while the average stood at $33.2 billion.
- Per our database at Business Quant, ADC Therapeutics' Invested Capital soared by 8265585267.64% in 2022 and then plummeted by 2407.01% in 2023.
- Over the past 4 years, ADC Therapeutics' Invested Capital (Quarter) stood at $23.8 million in 2019, then skyrocketed by 401.82% to $119.4 million in 2021, then surged by 324.08% to $506.3 million in 2022, then soared by 10822.48% to $55.3 billion in 2023.
- Its Invested Capital was $55.3 billion in Q3 2023, compared to $58.0 billion in Q2 2023 and $60.7 billion in Q1 2023.